Sutro Biopharma, Inc.
Price Action
Technical Summary
STAGE 2 UPTRENDSutro Biopharma, Inc. is in a confirmed Stage 2 uptrend, with price holding above all major moving averages and trend structure remaining intact. Relative strength is leading (RS Rating: 99), indicating clear outperformance against the broad market. Earnings contraction of 14% provides fundamental context to the price action. However, price is extended 43% above the 50-day line, increasing the risk of a mean reversion.
Trend Template (Minervini)
Price vs Moving Averages
| Period | Value | Spread | Signal |
|---|---|---|---|
| 20 SMA | $16.88 | +21.25% | ABOVE |
| 50 SMA | $14.27 | +43.44% | ABOVE |
| 100 SMA | $8.56 | +139.17% | ABOVE |
| 150 SMA | $6.00 | +241.29% | ABOVE |
| 200 SMA | $4.70 | +335.09% | ABOVE |
Price Performance
Technical Indicators
Risk Profile
Volume Analysis
Earnings Momentum
Growth Trends
Compounded Sales Growth
Compounded Profit Growth
Stock Price CAGR
Return on Equity
Key Metrics
Frequently Asked Questions
Is STRO in an uptrend right now?
STRO has a trend score of 4/4 based on Minervini's Stage Analysis. Yes, STRO is in a Stage 2 uptrend with price above all major moving averages (50, 100, 150, 200 SMA) properly stacked.
Is STRO overbought or oversold?
STRO's RSI (14) is 72. The stock is in overbought territory (RSI > 70), which may signal a pullback.
Is STRO outperforming the market?
STRO has a Relative Strength (RS) Rating of 99 out of 99. Yes, STRO is a market leader, outperforming 99% of all stocks over the past 12 months.
Where is STRO in its 52-week range?
STRO is trading at $20.47, which is 98% of its 52-week high ($20.93) and 98% above its 52-week low ($0.52).
How volatile is STRO?
STRO has a Beta of 1.22 and 52-week volatility of 126%. It's more volatile than the S&P 500 - expect bigger swings.